3b Blackbio Dx Ltd · NSE:3BBLACKBIO
3b Blackbio Dx — Investor Presentation (August 2024)
43 slides from 3b Blackbio Dx's investor presentation, Aug 12, 2024
Slide 1: Cover letter to BSE with investor presentation
(Formerly – Kilpest India Limited) Ref. No.P-66/2024-25/30 August 12, 2024 The Relationship Manager, Department of Corporate Relations BSE Limited, P.J. Towers, Dalal Street Fort, MUMBAI – 400 001 Dear Sir/Madam, Please find the enclosed herewith Investor’s Presentation / Company Update of Agrochemi
Slide 2: Investor Presentation August 2024
Formerly, Kilpest India Limited & 3B BlackBio Biotech India Limited Since 1972, 52 Years Strong Reliable and Affordable Healthcare Diagnostic Solutions Experts in Molecular Diagnostics throughout Europe INVESTOR PRESENTATION August, 2024
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which has been prepared by 3B BlackBio Dx Limited, formerly Kilpest India Limited and 3B BlackBio Biotech India Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer
Slide 4: Q1 FY 2024-25 Financial Performance and Key Highlights
Q1 FY 2024-25 FINANCIAL PERFORMANCE AND KEY HIGHLIGHTS
Slide 5: Performance Highlights – Q1 2024-25
Performance Highlights – Q1 2024-25 2,312.50 1,129.76 13.19 1,435.73 1,724.32 720.63 919.08 8.41 Q1 2023-24 Q1 2024-25 Q1 2023-24 Q1 2024-25 Q1 2023-24 Q1 2024-25 Q1 2023-24 Q1 2024-25 Total Sales / Revenue PBT PAT EPS Q1 FY 2023-24 Q1 FY 2024-25 Consolidated Q1 FY24 Q1 FY25 Total Revenue 1724.32 23
Slide 6: Key Highlights – Agrochemicals (Kilpest)
Key Highlights – Agrochemicals (Kilpest) Main Thrust Area of R&D Development of novel formulations for agriculture and public health which are less harmful and cost effective. Performance monitoring of existing products/process. Improvement in existing products/process with a customer driven a
Slide 7: Agrochemicals (Kilpest) - Existing Products
Agrochemicals (Kilpest) - Existing Products Chemicals Biologicals No. of Products No. of Products • Insecticides 70 • Bio pesticide 07 • Antibacterials 01 • Bio fungicide 01 • Fungicides 15 • Bio fertilizers 05 • Herbicides 11 • Bio nematicides 01 • Public Health 11 • Public Health 02 • Microfertili
Slide 8: Selected as part of Select 200 Companies
3B BlackBio has been selected as a part of “Select 200 Companies” with the global business potential at DGEMS2023 held in Delhi on 27th October 2023 presented by Forbes India & D Globalist. ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 9: Introduction
Introduction Incorporated in the year 2011, “3B BlackBio Dx Limited” formerly 3B BlackBio Biotech India Limited, is engaged in Design, Development, Manufacturing and Commercialization of Rapid tests, qPCR tests & NGS based Molecular Diagnostic Kits for reliable testing on patient samples. In the Y
Slide 10: TRUPCR from 3B BlackBio Dx Limited: Vision and Mission
TRUPCR® from 3B BlackBio Dx Limited Our Vision: Our Mission: To offer reliable, affordable and To design and develop molecular effective healthcare solutions to all by diagnostics products of superior quality recognizing the great potential of and value that continuously improves biotechnology to ef
Slide 11: TRUPCR Growth Story
TRUPCR® Growth Story Oncology Tests for BCR- Received Outstanding Launch of UTI ID & UTI AST ABL1 QT, JAK-2, PML- Achievement Award by Panels RARA Launched FMPCCI Breakthrough with US$200K Received “Award of NOVARTIS included TRUPCR® Kits accepted in order of TRUPCR® H1N1 Excellence” as a Leading TR
Slide 12: Growth Canvas: Sales in INR Millions
Growth Canvas Sales in INR Millions ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 13: Diagnostics Business - Financial Highlights – Q1 FY 2024-25
Diagnostics Business - Financial Highlights – Q1 FY 2024-25 1,694.44 1,458.53 898.43 1,202.89 Revenue from Operations EBITDA Q1 FY 2023-24 Q1 FY 2024-25 1,438.73 1,132.75 696.51 886.85 PBT PAT Rs. In Lakh. ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 14: Our Strategic Priorities
Our Strategic Priorities Portfolio Expansion: Market Penetration: Drawing upon our extensive research Our strategic initiative involves and development expertise, we aim to bolstering sales with existing enhance our product portfolio by customers and channel partners introducing new offerings in the
Slide 15: Business Outlook – Molecular Diagnostics (MDx)
Business Outlook – Molecular Diagnostics (MDx) Our Q1 Sales have been INR 1694.44 Lakh (This includes COVID Sales of INR 4.81 Lakh against INR 36.63 Lakh of Q1 2023-24). Sales from TRUPCR Europe Limited, Manchester for INR 325.84 Lakh have also been consolidated in the Q1 sales figures. In Q1 2024-2
Slide 16: Our Global Presence
Our Global Presence TRUPCR® assays have garnered widespread acceptance in more than 55 countries spanning the UK, Europe, the Middle East, APAC, LATAM, and North America (including the United States and Canada). Additionally, we have expanded into new territories across Europe, Africa, Southeast Asi
Slide 17: Exports / International Business
Exports / International Business Efforts are underway to continuously enhance our global presence by appointing new channel partners in various countries, thereby augmenting our international reach. Product registrations have been successfully completed in several countries, with ongoing processes i
Slide 18: Exports / International Business
Exports / International Business Our export business, particularly in non-COVID sales, has increased by over substantially in Q1 2024-25 against Q1 2023-24. This increase was due to certain tender business from last year which was materialized in the Q1 this year and substantial increase in business
Slide 19: Events & Conferences - International
Events & Conferences - International Our robust international presence is underscored by our active participation in numerous conferences, where we showcase our product range and unveil new product verticals. These conferences serve as invaluable platforms to engage with key stakeholders, forge part
Slide 20: Events & Conferences - International
Events & Conferences - International Our participation in the prestigious MEDLAB MIDDLE EAST 2024 conference, held from February 5th to 8th, 2024, at the World Trade Centre in Dubai, United Arab Emirates, has proven to be highly successful. At this event, we engaged in fruitful discussions with pros
Slide 21: Events & Conferences - India
Events & Conferences - INDIA Our participation in the esteemed APCON 2023 conference, held from December 6th-10th 2023, at the JLN Stadium, All India Institute of Medical Sciences (AIIMS), New Delhi, was highly impactful. Additionally, in November 2023, our team participated in MICROCON 2023 – LUCKN
Slide 22: Workshops - India
Workshops - INDIA Our sales, marketing, and application teams have been collaborating to organize a series of workshops for both existing users of our kits and prospective clients. These workshops aim to provide valuable insights into the usage and benefits of our products, facilitating enhanced und
Slide 23: TRUPCR Europe Limited - Manchester Site
TRUPCR® Europe Limited - Manchester Site Our UK Subsidiary, TRUPCR® Europe Limited growth of over 85% of revenue is a significant milestone, especially when it's driven by successful expansion efforts in new markets. Our UK team has been proactive and strategic in their approach to European expansio
Slide 24: TRUPCR Europe Limited - Manchester Site
TRUPCR® Europe Limited - Manchester Site TRUPCR Europe has been participating in international molecular diagnostic conferences and organizing training sessions and seminars for customers to showcase expertise, build relationships within the industry, and educate customers about its products and ser
Slide 25: What Sets us Apart!
What Sets us Apart! Leading Molecular Diagnostics (MDx) company in India Largest Product Range across Infectious & Oncology Assays Largest CE-IVD and Indian IVD Product Range Large, expansive and highly loyal customer base spread across government & private hospitals and labs in over 55 coun
Slide 26: Product Segments
Product Segments ONCOLOGY ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 27: Comprehensive Panels for Syndromic Testing
Comprehensive Panels for Syndromic Testing TRUPCR® Flu Panel with RSV The COVID-19 pandemic has underscored the importance of multiplex PCR assays Detection Kit and syndromic diagnostic testing for infectious diseases, highlighting their utility in rapidly diagnosing and managing contagious illnesse
Slide 28: Antimicrobial Resistance – A Silent Pandemic
Antimicrobial Resistance – A Silent Pandemic Antimicrobial resistance (AMR) has become one of the most significant threats to public health worldwide, often referred to as the "silent pandemic" due to its gradual and insidious nature. Image Source: AMR Action Fund • Encouraging judicious use of anti
Slide 29: Solutions by 3B BlackBio to combat Antimicrobial Resistance
Solutions by 3B BlackBio to combat Antimicrobial Resistance We offer an extensive range of RT-PCR-based and lateral flow assays that demonstrates our proactive approach to addressing the global concern of antimicrobial resistance (AMR). TRUPCR® have both singlex and multiplexing RT-PCR assays for th
Slide 30: TRURAPID AMR rapid tests
Solutions by 3B BlackBio to combat Antimicrobial Resistance We are pleased to inform that we have successfully completed the collaborative R&D of the Rapid Tests for Anti-Microbial Resistance (AMR). The below assays have been launched to cater to the AMR segment: TRURAPID® RESIST-5 OKNVI Rapid Tes
Slide 31: Next-Gen Sequencing (NGS) Vertical
Next-Gen Sequencing (NGS) Vertical We started working on NGS Kit development in 2019, had developed few parameters, but then COVID came and all activities were suspended. Now we are again reviving the NGS kits revalidations and also development of few more parameters, keeping in mind the global mark
Slide 32: Digital PCR
Digital PCR Our Research and Development (R&D) team is committed to the ongoing development of innovative products leveraging cutting- edge technologies. Through our dedication to scientific advancement and technological innovation, we strive to address emerging challenges and meet the evolving need
Slide 33: Long Term Contracts
Long Term Contracts Signing long-term contracts with large customers is a strategic move that provides stability and predictability to the business operations. By securing commitments for 2-3 years, we can better forecast revenue streams and plan resources accordingly, reducing uncertainty and mitig
Slide 34: Utilization of Funds
Utilization of Funds We have been looking for options to acquire a company in similar business area to get inorganic growth since FY22. M&A valuations globally have gone high due to demand from molecular diagnostic companies which are flushed with cash from COVID. We will only go for the acquisition
Slide 35: Quality & Regulatory
Quality & Regulatory ISO 13485:2016 & GMP Compliant manufacturing under the Medical Device QMS through BSI Licensed by CDSCO, Govt. Of India; equivalent to FDA, for our top-selling parameters in India Over 120 Parameters are CE-IVD marked ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUM
Slide 36: All Inclusive TRUPCR Products
All Inclusive TRUPCR® Products TRUPCR® range of products offers end-to-end standardized solutions from samples to optimized end-results Nucleic Acid Detection Sample Nucleic Acid Nucleic Acid Extraction & and Management Preparation Amplification Purification Analysis Sample stabilization TRUPCR ® Nu
Slide 37: Global Recognition
Global Recognition ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 38: A Notable Pharma Project
A Notable Pharma Project TRUPCR® BCR-ABL IS Kit along with its user labs, is a proud partner of NOVARTIS INDIA for its MAGIC BULLET, ® GLIVEC (imatinib mesylate) 150,000 Tests TRUPCR® BCR-ABL IS Kit for the NOVARTIS Patient Sponsorship / Trials ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEAL
Slide 39: 3B – In Publications
3B – In Publications Many more studies are under publication ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 40: Growth Drivers
Growth Drivers • Improvement in Indian healthcare industry with high demand in medical tourism • Increasing number of molecular tests being introduced by labs • Evolution of disease profiles. New viruses and cancers are been diagnosed External Growth Drivers • Increase in evidence-based treatments /
Slide 41: Outstanding Achievement Award for Excellence in R&D by FMPCCI
Outstanding Achievement Award for Excellence in R&D by FMPCCI, Bhopal - 2022 3B BlackBio Biotech India Limited received the Outstanding Achievement Award – 2021 by the Honorable Governor of Madhya Pradesh, His Excellency Shri Mangubhai Patel. The award was conferred to us in recognition of our conti
Slide 42: National MSME Award 2018
National MSME Award- 2018 by Hon'ble President of India, Shri Ram Nath Kovind. Hon'ble President of India, Shri Ram Nath Kovind on Friday on the occasion of 20th National Technology Day presented the national award for successful commercialization of indigenous technology at Vigyan Bhavan, New Delhi
Slide 43: Jai Hind
JAI HIND ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS